PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).

被引：11

作者：

Zhang, Tian

Ballman, Karla V.

Choudhury, Atish Dipankar

Chen, Ronald C.

Watt, Colleen

Wen, Yujia

Zemla, Tyler

Emamekhoo, Hamid

Gupta, Shilpa

Morris, Michael J.

George, Daniel J.

Choueiri, Toni K.

机构：

[1] Duke Univ, Med Ctr, Durham, NC USA

[2] Weill Cornell Med, New York, NY USA

[3] Dana Farber Canc Inst, Boston, MA 02115 USA

[4] Univ N Carolina, Chapel Hill, NC 27515 USA

[5] Univ Chicago, Chicago, IL 60637 USA

[6] Mayo Clin, Rochester, MN USA

[7] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA

[8] Univ Minnesota, Dept Med, Masonic Canc Ctr, Box 736 UMHC, Minneapolis, MN 55455 USA

[9] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[10] Duke Univ, Inst Canc, Durham, NC USA

[11] Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA

[12] Harvard Med Sch, Boston, MA 02115 USA

来源：

关键词：

D O I：

10.1200/JCO.2019.37.15_suppl.TPS4596

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

TPS4596

引用

页数：2